[1]
|
Siegel, R.L., Miller, K.D., Goding Sauer, A., Fedewa, S.A., Butterly, L.F., Anderson, J.C., Robert, A.S. and Ahmedin, J.D. (2020) Colorectal Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 145-164. https://doi.org/10.3322/caac.21601
|
[2]
|
Petrackova, A., Turcsanyi, P., Papajik, T. and Kriegova, E. (2021) Revisiting Richter Transformation in the Era of Novel CLL Agents. Blood Reviews, 49, Article ID: 100824. https://doi.org/10.1016/j.blre.2021.100824
|
[3]
|
Chen, P., El Hussein, S., Xing, F., Aminu, M., Kannapiran, A., Hazle, J.D., Medeiros, L.J., Wistuba, I.I., Jaffray, D., Khoury, J.D. and Wul, J. (2022) Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. Cancers, 14, Article 2398. https://doi.org/10.3390/cancers14102398
|
[4]
|
Pugh, W.C., Manning, J.T. and Butler, J.J. (1988) Paraimmunoblastic Variant of Small Lymphocytic Lymphoma/Leukemia. The American Journal of Surgical Pathology, 12, 907-917. https://doi.org/10.1097/00000478-198812000-00002
|
[5]
|
Gine, E., Martinez, A., Villamor, N., Lopez-Guillermo, A., Camos, M., Martinez, D., Esteve, J., Calvo, X., Muntanola, A., Abrisqueta, P., Rozman, M., Rozman, C., Bosch, F., Campo, E. and Montserrat, E. (2010) Expanded and Highly Active Proliferation Centers Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” Chronic Lymphocytic Leukemia) with Aggressive Clinical Behavior. Haematologica, 95, 1526-1533. https://doi.org/10.3324/haematol.2010.022277
|
[6]
|
Xie, J., Jang, A., Vegel, A., Hajja, Y., Mouawad, Y., Baghian, A., Berbari, B., Schmid, J.L., Socola, F., Safah, H. and Saba, N.S. (2021) Successful Treatment of “Accelerated” Chronic Lymphocytic Leukemia with Single Agent Ibrutinib: A Report of Two Cases. Leukemia Research Reports, 15, Article ID: 100247.
https://doi.org/10.1016/j.lrr.2021.100247
|
[7]
|
Matutes, E. and Polliack, A. (2000) Morphological and Immunophenotypic Features of Chronic Lymphocytic Leukemia. Reviews in Clinical and Experimental Hematology, 4, 22-47. https://doi.org/10.1046/j.1468-0734.2000.00002.x
|
[8]
|
Boyd, S.D., Natkunam, Y., Allen, J.R. and Warnke, R.A. (2013) Selective Immunophenotyping for Diagnosis of B-Cell Neoplasms. Applied Immunohistochemistry & Molecular Morphology, 21, 116-131.
https://doi.org/10.1097/PAI.0b013e31825d550a
|
[9]
|
Soilleux, E.J., Wotherspoon, A., Eyre, T.A., Clifford, R., Cabes, M. and Schuh, A.H. (2016) Diagnostic Dilemmas of High-Grade Transformation (Richter’s Syndrome) of Chronic Lymphocytic Leukaemia: Results of the Phase II National Cancer Research Institute CHOP-OR Clinical Trial Specialist Haemato-Pathology Central Review. Histopathology, 69, 1066-1076. https://doi.org/10.1111/his.13024
|
[10]
|
Garces, S., Khoury, J.D., Kanagal-Shamanna, R., Salem, A., Wang, S.A., Ok, C.Y., Hu, S., Patel, K.P., Routbort, M.J., Luthra, R., Tang, G., Schlette, E.J., Bueso-Ramos, C.E., Medeiros, L.J. and Loghavi, S. (2018) Chronic Lymphocytic Leukemia with Proliferation Centers in Bone Marrow Is Associated with Younger Age at Initial Presentation, Complex Karyotype, and TP53 Disruption. Human Pathology, 82, 215-231.
https://doi.org/10.1016/j.humpath.2018.07.030
|
[11]
|
Ciccone, M., Agostinelli, C., Rigolin, G.M., Piccaluga, P.P., Cavazzini, F., Righi, S., Sista, M.T., Sofritti, O., Rizzotto, L., Sabattini, E., Fioritoni, G., Falorio, S., Stelitano, C., Olivieri, A., Attolico, I., Brugiatelli, M., Zinzani, P.L., Saccenti, E., Capello, D., Negrini, M., Cuneo, A. and Pileri, S. (2012) Proliferation Centers in Chronic Lymphocytic Leukemia: Correlation with Cytogenetic and Clinicobiological Features in Consecutive Patients Analyzed on Tissue Microarrays. Leukemia, 26, 499-508.
https://doi.org/10.1038/leu.2011.247
|
[12]
|
Khan, M., Siddiqi, R. and Thompson, P.A. (2018) Approach to Richter Transformation of Chronic Lymphocytic Leukemia in the Era of Novel Therapies. Annals of Hematology, 97, 1-15. https://doi.org/10.1007/s00277-017-3149-9
|
[13]
|
Schroers, R., Griesinger, F., Trümper, L., Haase, D., Kulle, B., Klein-Hitpass, L., Sellmann, L., Dührsen, U. and Dürig, J. (2005) Combined Analysis of ZAP-70 and CD38 Expression as a Predictor of Disease Progression in B-Cell Chronic Lymphocytic Leukemia. Leukemia, 19, 750-758. https://doi.org/10.1038/sj.leu.2403707
|
[14]
|
Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., Bühler, A., Edelmann, J., Bergmann, M., Hopfinger, G., Hensel, M., Hallek, M., Dohner, H. and Stilgenbauer, S. (2010) TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 28, 4473-4479.
https://doi.org/10.1200/JCO.2009.27.8762
|
[15]
|
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. and Stilgenbauer, S. (2010) Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukaemia: A Randomised, Open-Label, Phase 3 Trial. The Lancet, 376, 1164-1174.
https://doi.org/10.1016/S0140-6736(10)61381-5
|
[16]
|
O’Brien, S., Furman, R.R., Coutre, S., Flinn, I.W., Burger, J.A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., Heerema, N.A., Johnson, A.J., Luan, Y., James, D.F., Chu, A.D. and Byrd, J.C. (2018) Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience. Blood, 131, 1910-1919. https://doi.org/10.1182/blood-2017-10-810044
|
[17]
|
Tsang, M., Shanafelt, T.D., Call, T.G., Ding, W., Chanan-Khan, A., Leis, J.F., Nowakowski, G.S., Bowen, D., Conte, M., Schwager, S.M., Slager, S.L., Kay, N.E., Hanson, C.A. and Parikh, S.A. (2015) The Efficacy of Ibrutinib in the Treatment of Richter Syndrome. Blood, 125, 1676-1678.
https://doi.org/10.1182/blood-2014-12-610782
|
[18]
|
Fischer, A., Bastian, S., Cogliatti, S., Mey, U., Saub, J., Schanz, U., Padberg, B. and Hohloch, K. (2018) Ibrutinib-Induced Rapid Response in Chemotherapy-Refractory Richter’s Syndrome. Hematological Oncology, 36, 370-371.
https://doi.org/10.1002/hon.2464
|
[19]
|
Maddocks, K.J., Ruppert, A.S., Lozanski, G., Heerema, N.A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L.L., Mantel, R., Jones, J.A., Flynn, J.M., Jaglowski, S.M., Andritsos, L.A., Awan, F., Blum, K.A., Grever, M.R., Johnson, A.J., Byrd, J.C. and Woyach, J.A. (2015) Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients with Chronic Lymphocytic Leukemia. JAMA Oncology, 1, 80-87. https://doi.org/10.1001/jamaoncol.2014.218
|